LUND, Sweden – Cellevate AB, an innovative biotech company that develops the next generation of cell culture systems designed to revolutionize biomanufacturing, today announces that the company has entered into collaboration with the Max Planck Society, represented by the Max Planck Institute for Dynamics of Complex Technical Systems in Magdeburg, Germany. The Max Planck Society has a world-leading reputation as a science and technology research organization, with over 30 Nobel Prizes awarded to their scientists, and is widely regarded as one of the foremost basic research organizations in the world.
The collaborative research program with the Bioprocess Engineering Group of the Max Planck Institute is focused on the use of Cellevat3d™ carriers in vaccine production and aims to identify suitable carrier formats, functionalization, and bioreactor type. The program includes evaluating the growth of e.g., Vero cells on the carriers and subsequent virus production, optimizing the process, and scaling it up in bioreactors. Successful completion of this research program aims at a joint publication of the evaluation findings. PD Dr. Yvonne Genzel, member of the Bioprocess Engineering group at the Max Planck Institute who is head of the Upstream Processing Team, will be the principal investigator. PD Dr. Genzel has recently joined Cellevate’s Scientific Advisory Board.
“The estimated value of the vaccines market for carriers is over 300 MUSD, and this research program with Max Planck Institute and PD Dr. Yvonne Genzel gives us a tremendous opportunity and an entry door into this market. It offers an additional avenue for commercial success for our Cellevat3d™ carriers in 2024″, says Laura Chirica, CEO Cellevate.
For more information, please contact:
Laura Chirica, PhD
About Max Planck Institute for Dynamics of Complex Technical Systems
The Max Planck Institute for Dynamics of Complex Technical Systems was established in 1996. The institute in Magdeburg is the first institute of the Max Planck Society dedicated to the engineering sciences and is intended to bridge the gap between basic research and industrial applications. Research activities are focused on the investigation and development of new approaches for the synthesis, analysis, and control of highly complex processes in biotechnology, chemical production, and energy conversion. Scientists from different disciplines such as process engineering, chemistry, biology, mathematics, and computer sciences add their specific knowledge to the research work, thereby developing new methods and tools for solving challenging problems in various application areas.
For more information, please visit www.mpi-magdeburg.mpg.de/bpe.
Cellevate is a spin out from NanoLund – a world leading nanomaterial academic center. The company founded in 2014, develops and markets products based on a proprietary nanofiber-based platform – the Cellevat3d™ – a game-changing, green and sustainable, deep-tech innovation for the biopharmaceutical industry. This platform allows for an industrial-scale production of carriers with unparalleled surface area for cell growth, reproducibility and customization. Cellevat3d™ carriers products are designed for laboratory testing of cell lines as well as pilot and large-scale batch production of novel classes of biological therapies, including cell- and gene therapies and vaccines. Cellevat3d™ carriers have a commercial launch and sales start planned for 2024.
For more information, please visit www.cellevate.com.